Nosocomial COVID-19 Infections in Patients Hospitalized at the Metz-Thionville Regional Hospital in 2021

NCT05567874 | Completed

• 1 other identifier: 2022-09Obs-CHRMT
• Study Type: observational
• Target: 216
• Locations: 1 country
• Sites: 1

Brief Summary

The rate of nosocomial SARS-CoV2 infections found in the different studies since the beginning of the pandemic is very variable (\<1% in hospitals in the USA to about 20% in a British hospital). Mortality related to these nosocomial SARS-CoV2 infections is higher than in the general population. The risk factors identified for this nosocomial acquisition are multiple. We were confronted with nosocomial acquisitions and cluster situations in the services, without exhaustive data to measure these phenomena, and we lacked data to consider areas for improvement. The objectives of this study are to determine the proportion of nosocomial SARS COV 2 infections in the total number of patients hospitalized with a Covid-19 infection at the CHR Metz-Thionville in 2021, and to describe the characteristics of this population.

Conditions

SARS CoV 2 Infection

Outcome Measures

Primary Outcomes (1)

• Proportion of hospital-acquired infections in patients hospitalised with a covid-19 infection

  Several elements are taken into account: a) the time between entry into the establishment and the first positive SARS COV 2 PCR, b) the time between entry into the establishment and the appearance of the most frequent symptoms (fever, cough), if present in the patient, in the seven days preceding the first positive SARS COV 2 PCR, c) the existence of an epidemiological link with other infected patients, via contact in a double room with another case, and/or via hospitalisation in a department concerned by a cluster situation according to the Santé Publique France definition of May 2020 (identified on the basis of monitoring and surveillance data from the hygiene department).

  up to 8 months after the third COVID-19 wave

Secondary Outcomes (1)

• Description of the nosocomial infected population

  up to 8 months after the third COVID-19 wave

Study Arms (3)

SARS-CoV 2 infected patients hospitalized at CHR Metz-Thionville in 2021 during the first period

SARS-CoV 2 infected patients hospitalized at CHR Metz-Thionville in April 2021

Other: Nosocomial SARS-COV 2 Infection proportion

SARS-CoV 2 infected patients hospitalized at CHR Metz-Thionville in 2021 during the second period

SARS-CoV 2 infected patients hospitalized at CHR Metz-Thionville from June to September 2021

Other: Nosocomial SARS-COV 2 Infection proportion

SARS-CoV 2 infected patients hospitalized at CHR Metz-Thionville in 2021 during the third period

SARS-CoV 2 infected patients hospitalized at CHR Metz-Thionville in December 2021

Other: Nosocomial SARS-COV 2 Infection proportion

Interventions

Nosocomial SARS-COV 2 Infection proportion OTHER

Proportion of Nosocomial SARS-COV 2 Infections in Patients Hospitalized at the Metz-Thionville Regional Hospital in 2021

SARS-CoV 2 infected patients hospitalized at CHR Metz-Thionville in 2021 during the first period; SARS-CoV 2 infected patients hospitalized at CHR Metz-Thionville in 2021 during the second period; SARS-CoV 2 infected patients hospitalized at CHR Metz-Thionville in 2021 during the third period

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Hospitalized patients with Covid-19 infection

You may qualify if:

• Patients hospitalised at the CHR Metz-Thionville in medicine, surgery and obstetrics (MCO) or geriatric follow-up and rehabilitation care (SSR) units, in 2021 for a Covid-19 infection defined by the existence of a positive PCR result for SARS-CoV2 during the stay, or by the existence of an ICD10 code for COVID in the PMSI data of the health care establishment

You may not qualify if:

• Opposition to participate in the study after reading the patient information note.

Sponsors & Collaborators

• Centre Hospitalier Régional Metz-Thionville: lead

Study Sites (1)

CHR Metz-Thionville/Hopital de Mercy

Metz, 57085, France

Location

MeSH Terms

Conditions

COVID-19

Condition Hierarchy (Ancestors)

Pneumonia, Viral; Pneumonia; Respiratory Tract Infections; Infections; Virus Diseases; Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Lung Diseases; Respiratory Tract Diseases

Study Officials

• Mathieu LLORENS, MD

  CHR Metz Thionville Hopital de Mercy

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 3, 2022
• First Posted: October 5, 2022
• Study Start: January 3, 2022
• Primary Completion: March 31, 2022
• Study Completion: August 31, 2022
• Last Updated: May 6, 2023

Record last verified: 2022-10

Locations

FR (1)